New OMICmAge Test Predicts Disease Risk and Mortality Using DNA Methylation Data
Scientists developed OMICmAge, a biological age test that integrates multiple data types to predict chronic disease risk and mortality better than existing biomarkers.
Summary
Researchers developed OMICmAge, a new biological age test that measures how fast you're aging at the cellular level. Using DNA methylation patterns from over 31,000 people, the test integrates data from proteins, metabolites, and medical records to predict disease risk and mortality. In validation studies across 36,000 participants, OMICmAge outperformed existing aging biomarkers at predicting chronic diseases and death risk. The test works by analyzing epigenetic changes - chemical modifications to DNA that accumulate with age and reflect biological wear and tear. What makes OMICmAge unique is that it captures aging across multiple biological systems while requiring only a simple DNA methylation test, making it potentially accessible for routine health monitoring.
Detailed Summary
Biological aging happens at different rates in different people, and measuring this process accurately could revolutionize how we approach health and longevity. Traditional chronological age tells us little about actual health status or disease risk.
Researchers from Harvard Medical School and TruDiagnostic analyzed data from over 31,000 participants across multiple cohorts to develop OMICmAge, a comprehensive biological age test. They first created EMRAge using routine lab values from electronic medical records, then enhanced it by integrating DNA methylation patterns, protein levels, and metabolic markers.
The team validated OMICmAge across three independent cohorts totaling 36,336 participants. The test demonstrated superior performance compared to existing biological age markers in predicting mortality risk and chronic diseases including cardiovascular disease, diabetes, and cancer. Importantly, OMICmAge can be calculated using DNA methylation data alone, making it practically accessible.
OMICmAge works by measuring epigenetic changes - chemical modifications to DNA that accumulate with age and reflect cellular damage, inflammation, and metabolic dysfunction. The algorithm integrates these patterns with proxies for protein and metabolite levels, creating a comprehensive picture of biological aging across multiple organ systems.
For longevity-focused individuals, OMICmAge could enable precise tracking of aging interventions like diet, exercise, supplements, or medications. The test might identify people aging rapidly before symptoms appear, allowing earlier interventions. However, the study was conducted primarily in populations of European ancestry, potentially limiting generalizability. Additionally, while the test predicts health outcomes well, more research is needed to determine how effectively it tracks responses to anti-aging interventions.
Key Findings
- OMICmAge outperformed existing biological age tests in predicting mortality and chronic disease risk
- The test integrates DNA methylation, protein, and metabolic data while requiring only methylation testing
- Validation across 36,000+ participants confirmed superior predictive accuracy for health outcomes
- OMICmAge captures aging across multiple biological systems using accessible testing methods
Methodology
Researchers analyzed data from 31,000 participants in the Mass General Brigham Biobank to develop EMRAge, then enhanced it with multi-omics data. Validation occurred across three independent cohorts totaling 36,336 participants using elastic net regression modeling.
Study Limitations
The study was conducted primarily in populations of European ancestry, potentially limiting applicability to other ethnic groups. Long-term studies are needed to validate how well OMICmAge tracks responses to anti-aging interventions and lifestyle changes.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.